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ABSTRACT
Secondary peritonitis includes community-acquired and nosocomial peritonitis. These intra-abdominal
infections have a common pathogenesis but some microbiological differences, particularly with respect
to the type of bacteria recovered and the level of antimicrobial susceptibility. This report describes a
prospective observational study of 93 consecutive patients with secondary peritonitis during an 11-
month period. Community-acquired peritonitis accounted for 44 cases and nosocomial peritonitis for 49
cases (post-operative in 35 cases). Fifteen multidrug-resistant (MDR) bacteria were recovered from 14
patients. In univariate analysis, the presence of MDR bacteria was associated signiﬁcantly with pre-
operative and total hospital lengths of stay, previous use of antimicrobial therapy, and post-operative
antimicrobial therapy duration and modiﬁcations. A 5-day cut-off in length of hospital stay had the best
speciﬁcity (58%) and sensitivity (93%) for predicting whether MDR bacteria were present. In
multivariate analysis, only a composite variable associating pre-operative hospital length of stay and
previous use of antimicrobial therapy was a signiﬁcant independent risk-factor for infection with MDR
bacteria. In conclusion, knowledge of these two factors may provide a more rational basis for selecting
initial antimicrobial therapy for patients with secondary peritonitis.
Keywords Antibiotic resistance, multiresistance, peritonitis, risk-factors, therapy
Original Submission: 3 October 2005; Revised Submission: 14 December 2005; Accepted: 14 January 2006
Clin Microbiol Infect 2006; 12: 980–985
INTRODUCTION
Secondary peritonitis is a common disease that
includes a broad variety of pathological condi-
tions, including community-acquired peritonitis
and nosocomial peritonitis (including post-opera-
tive peritonitis) [1]. A perforation of the gastroin-
testinal tract, with or without a previous surgical
intervention, is characteristic of all of these intra-
abdominal infections. However, these infections
have some microbiological differences in terms of
the spectrum of bacteria involved and their level
of antibiotic susceptibility [2–6]. For example,
Escherichia coli is recovered less frequently from
cases of post-operative peritonitis than from cases
of community-acquired peritonitis, whereas Ent-
erococcus spp. and Enterobacter spp. are recovered
more frequently from cases of post-operative
peritonitis. Moreover, multidrug-resistant (MDR)
bacteria are recovered more frequently from cases
of post-operative peritonitis. In this context,
resistant and MDR bacteria were shown to be
present in 70% and 37% of cases, respectively [2].
Preceding antibiotic use may also play a role by
modifying the spectrum of the bacterial ﬂora and
the level of antibiotic susceptibility [3].
These data have resulted in the proposal of
antimicrobial regimens with an extended spec-
trum for cases of post-operative peritonitis, and
also for patients with a prolonged pre-operative
hospital stay and prolonged (>2 days) pre-opera-
tive antimicrobial therapy [7]. Nevertheless, such
an approach could lead to excessive prescribing of
expensive broad-spectrum antibiotics. Indeed, it
has been demonstrated that the microbiological
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ﬁndings for nosocomial non-post-operative peri-
tonitis are quite similar to those for community-
acquired peritonitis, although a low proportion of
nosocomial ﬂora was nevertheless present [6]. In
this context, the present report describes a pros-
pective study to determine the risk-factors for
infection by MDR bacteria in secondary perito-
nitis in order to determine a more suitable initial
therapeutic approach.
MATERIALS AND METHODS
This prospective observational study was conducted between
1 November 2003 and 1 October 2004 in a 1980-bed teaching
hospital that serves as both a referral centre and a primary-care
centre. The hospital has one department of gastrointestinal
surgery, dealing mainly with patients with hepatobiliary
defects and malignancies, and one surgical intensive care unit,
which operates as a closed unit. The study was submitted to
the local ethical committee, which decided that informed
consent was not necessary.
All adult (aged ‡15 years) patients admitted for secondary
peritonitis, deﬁned as diffuse peritonitis originating from a
defect in the abdominal viscus [1], were included in the study.
Patients who did not undergo bacteriological investigation, and
those with pancreatitis or gynaecological infections, were
excluded. The origin of the peritonitis was determined (stom-
ach ⁄duodenum, small bowel, colon, appendix or biliary). In
cases of post-operative peritonitis attributed to anastomosis
leakage, the origin was deﬁned by the most contaminated site.
Peritonitiswas classiﬁedas community-acquiredornosocomial,
and in the latter case, as post-operative or non-post-operative.
The following data were recorded within 24 h of the
diagnosis of secondary peritonitis: age; gender; severity of
the underlying disease, deﬁned according to the criteria of
McCabe and Jackson [8] as not fatal (class 1), ultimately fatal
(class 2), and fatal (class 3); Simpliﬁed Acute Physiologic Score
II (SAPS II) [9]; and Acute Physiology and Chronic Health
Evaluation II (APACHE II) score [10]. The presence of septic
shock and ⁄ or bloodstream infection, and ⁄ or acute respiratory
distress syndrome, and ⁄ or acute renal failure, was also
recorded. Pre-operative hospital stay and previous use of
antimicrobial therapy before surgical treatment for peritonitis
were noted. Duration and modiﬁcations of post-operative
antimicrobial therapy, total length of hospital stay and mor-
tality at day +30 were also recorded. During the post-operative
period, any digestive complications or need for further surgery
were recorded.
Two blood cultures (aerobic and anaerobic) were taken
during the perioperative period. One or more peritoneal ﬂuid
sample(s) were also taken during surgery. These samples were
inoculated on to an aerobic medium (trypticase soya agar) and
an anaerobic medium (blood agar) and incubated at 37C.
Antibiotic susceptibilities of bacterial isolates were determined
by the disk-diffusion method (Bio-Rad, Marnes la Coquettes,
France), according to the recommendations of the Antibiogram
Committee of the French Microbiology Society (CA-SFM;
http://www.sfm.assoc.fr). The bacteria were then classiﬁed
as susceptible or resistant (resistant and intermediately-resist-
ant combined). The susceptibilities of aerobic Gram-negative
bacteria were determined for 13 antibiotics (amoxycillin,
amoxycillin–clavulanic acid, ticarcillin, ticarcillin–clavulanic
acid, piperacillin, piperacillin–tazobactam, cefotaxime, ceftaz-
idime, cefepime, imipenem, gentamicin, amikacin and cipro-
ﬂoxacin). The susceptibilities of three aerobic Gram-positive
bacteria (Enterococcus spp., Staphylococcus aureus, Streptococcus
spp.) were determined for oxacillin (Staph. aureus, Streptococcus
spp.), amoxycillin (Enterococcus spp.), vancomycin (Enterococ-
cus spp., Staph. aureus, Streptococcus spp.), and gentamicin
(Enterococcus spp., Streptococcus spp.). Enterobacteria with an
intermediately-resistant or resistant result for a third-genera-
tion cephalosporin were screened systematically for the pres-
ence of extended-spectrum b-lactamases by the double-disk
diffusion method, as described previously [11]. The suscepti-
bilities of anaerobic bacteria were not studied.
Surgical chemoprophylaxis was prescribed according to the
recommendations of the French Society of Anaesthesia and
Intensive Care [12] and was managed by the anaesthesiologist.
No antibiotic was added when intra-abdominal wash-out was
performed by the surgeons. In this institution, the ﬁrst-line
antimicrobial therapy was a combination of cefotaxime and
metronidazole for cases of community-acquired peritonitis,
and a combination of ticarcillin–clavulanic acid and amikacin
for cases of nosocomial peritonitis (both post-operative and
non-post-operative).
Deﬁnitions
Nosocomial intra-abdominal infection was deﬁned as an
infection absent upon admission that became evident in
patients 48 h or more after admission [13]. Prior antibiotic
use was deﬁned as the use of at least one antimicrobial agent
for >2 days during the 15-day period preceding the intra-
abdominal infection. Bloodstream infection was deﬁned as at
least one positive blood culture (two positive cultures in the
case of coagulase-negative staphylococci) reported as secon-
dary to the intra-abdominal infection, unless another source of
systemic infection, from which the bacteria was cultured, was
known. Septic shock was deﬁned according to the Bone criteria
[14], and acute respiratory distress syndrome was deﬁned
according to international consensus [15]. Acute renal failure
was deﬁned as a serum creatinine concentration >240 lmol ⁄L
and a serum urea concentration >16 mmol ⁄L and ⁄or a urine
output <400 mL ⁄ 24 h and ⁄or the need for dialysis. In the event
of chronic renal failure, acute renal failure was deﬁned as an
increase in creatinine of >120 lmol ⁄L or urea >8 mmol ⁄L
and ⁄ or a urine output <400 mL ⁄ 24 h and ⁄or the need for
dialysis [16]. MDR bacteria was deﬁned as: methicillin-resist-
ant Staph. aureus (MRSA); Enterococcus spp. resistant to vanco-
mycin and to high levels of gentamicin; Enterobacteriaceae
producing an extended-spectrum b-lactamase (e.g., Klebsiella
spp., Enterobacter spp., Esch. coli and Proteus mirabilis) or
producing a cephalosporinase (Enterobacter spp. and Serratia
spp.); Pseudomonas aeruginosa resistant to ticarcillin,
ceftazidime, imipenem or ciproﬂoxacin, or producing an
extended-spectrum b-lactamase; and Acinetobacter spp. resist-
ant to imipenem and ⁄ or ticarcillin and ⁄ or aminoglycosides.
Statistical analysis
Statistical analysis was performed using SAS Software v.8.02
(SAS Institute, Cary, NC, USA). Data are presented as
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means ± SD for continuous variables, and the number with the
corresponding percentage for qualitative variables. The char-
acteristics of patients infected with MDR bacteria, and those
who were not, were compared using Student’s t-test or
Wilcoxon’s rank sum test, as appropriate, for continuous
variables, and the chi-square or Fisher’s exact test, as appropri-
ate, for categorical variables. To identify risk-factors associated
independently with the occurrence of MDR bacteria, variables
found to be signiﬁcantly different between the two groupswere
entered into a forward stepwise logistic regression model. Each
variable used in this logistic regression analysis concerned
patients’ characteristic before isolation of MDR and was binary;
therefore, continuous variables were recoded by using receiver
operating characteristic curves to deﬁne the cut-off point
(represented by the value with the best sensitivity and specif-
icity). Pairwise interactions were tested between the variables.
In case of a signiﬁcant interaction, a composite variable was
created from the two corresponding variables. For all analyses,
p <0.05 was considered to be signiﬁcant.
RESULTS
Ninety-three patients were recruited during the
study period. Community-acquired peritonitis
accounted for 44 cases, and nosocomial peritonitis
for 49 cases (post-operative in 35 cases). None of
the cases of community-acquired peritonitis had a
history of recent hospitalisation and ⁄ or antibiotic
use. Community-acquired peritonitis was mainly
appendicular (22 cases), followed by colic, upper
bowel and biliar (12 cases, nine cases and one
case, respectively). Nosocomial peritonitis in-
volved primarily the colon (29 cases), followed
by the upper bowel, biliary tract and appendix
(15 cases, four cases and one case, respectively).
Microorganisms recovered from intraperitoneal
specimens are listed in Table 1. The distribution
of the microorganisms differed according to the
aetiology of the peritonitis.
Table 2 summarises the characteristics of
patients with and without MDR bacteria. In
univariate analysis, the risk for acquiring an
MDR organism was associated signiﬁcantly with
a higher severity of underlying disease, as
assessed by the McCabe index and the APA-
CHE II score. In contrast, SAPS II was not asso-
ciated with isolation of MDR bacteria, which
occurred more frequently in cases of post-opera-
tive peritonitis. Pre-operative length of hospital
stay and previous use of antimicrobial therapy, as
well as the duration and modiﬁcations of post-
operative antimicrobial therapy, were also asso-
ciated signiﬁcantly with the presence of MDR
bacteria. Length of hospital stay was longer when
an MDR bacterium was isolated, but mortality
rates at day 30 did not differ between the two
groups. Post-operative intra-abdominal complica-
tions were more frequent in patients with MDR
Table 1. Number of microorganisms recovered from
intraperitoneal samples
Community-
acquired
peritonitis
Nosocomial peritonitis
Post-operative Non-post-operative
Aerobes
Gram-negative
Escherichia coli 30 17 5
Klebsiella spp. 8 6 1
Pseudomonas aeruginosa 5 6 2
Enterobacter spp. 1 9 0
Proteus spp. 1 1 0
Acinetobacter spp. 0 0 0
Other bacteria 4 1 0
Gram-positive
Streptococcus spp. 15 11 3
Enterococcus spp. 7 21 7
Staphylococcus spp. 0 6 0
Anaerobes
Bacteroides fragilis 13 13 2
Clostridium spp. 2 3 2
Other bacteria 4 1 0
Candida spp.a 3 5 3
aAll cases were Candida albicans except for the cases of post-operative peritonitis,
which comprised C. albicans (n = 3), Candida glabrata (n = 1) and Candida krusei
(n = 1).
Table 2. Characteristics of the patients included in the
study, grouped according to the presence or absence of
multidrug resistant bacteria
Multidrug
resistance (–)
(n = 79)
Multidrug
resistance (+)
(n = 14) p
Age (years; mean ± SD) 59 ± 21 59 ± 23 0.817
Gender (M ⁄ F) 43 ⁄ 36 10 ⁄ 4 0.236
McCabe index 0.029
1 35 (44) 3 (21)
2 33 (42) 5 (36)
3 11 (14) 6 (43)
APACHE II score 14 ± 9 18 ± 7 0.040
SAPS II score 37 ± 18 43 ± 16 0.232
Septic shock 12 (15) 4 (29) 0.252
Bloodstream infection 11 (14) 3 (21) 0.437
ARDS 3 (4) 1 (7) 0.485
Acute renal failure 7 (9) 0 (0) 0.589
Type of peritonitis 0.003
Community-acquired 42 (53) 2 (14)
Post-operative 24 (30) 11 (79)
Non-post-operative 13 (17) 1 (7)
Pre-operative length
of hospital stay
(days; mean ± SD)
7 ± 8 23 ± 25 <0.001
Previous use of
antimicrobial therapya
27 (34) 10 (71) <0.001
Post-operative duration of
antimicrobial therapy
(days; mean ± SD)
10 ± 4 15 ± 8 <0.005
Post-operative antimicrobial
therapy modiﬁcations
27 (34) 14 (100) <0.001
Total length of hospital stay
(days; mean ± SD)
25 ± 17 47 ± 26 <0.001
Mortality at day +30 16 (20) 3 (21) 0.919
SAPS II, Simpliﬁed Acute Physiologic Score II; APACHE II, Acute Physiology and
Chronic Health Evaluation II; ARDS, acute respiratory distress syndrome. All data
are expressed in n (%) unless otherwise noted.
aAntimicrobial therapy administered for 2 days in the 15-day period preceding
secondary peritonitis.
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bacteria (78% vs. 32%; p <0.001), and especially
in those with infectious complications (57% vs.
19%; p 0.005). Further surgery was required by
14% of patients in both groups.
Pre-operative length of hospital stay was trans-
formed into a binary variable using a cut-off point
of 5 days, as determined with the receiver oper-
ating characteristic curve, to give the best specif-
icity (58%) and sensitivity (93%). A signiﬁcant
interaction was observed between pre-operative
length of hospital stay and previous use of
antimicrobial therapy. Consequently, a composite
variable was created that included three modal-
ities (pre-operative length of hospital stay
<5 days, pre-operative length of hospital stay
‡5 days without previous use of antimicrobial
therapy, and pre-operative length of hospital stay
‡5 days with previous use of antimicrobial
therapy). In the ﬁrst modality, previous use of
antimicrobial therapy was not taken into account
because only one patient developed an MDR
bacterial infection. In multivariate analysis, only
the composite variable was found to be a
signiﬁcant independent risk-factor for MDR bac-
terial infection, showing that patients with a pre-
operative length of hospital stay of ‡5 days had a
higher risk for developing an MDR bacterial
infection, especially when antibiotics had been
used previously (Table 3).
Fifteen MDR bacteria were isolated from 14
patients (Enterobacter aerogenes and P. aeruginosa
from one patient). The bacteria isolated were
Enterobacter spp. (n = 8; two Ent. aerogenes, six
Enterobacter cloacae); MRSA (n = 3); P. aeruginosa
(n = 2); Enterococcus spp. (n = 1); and Esch. coli
(n = 1) (Table 3).
The susceptibilities of the aerobic Gram-negat-
ive and Gram-positive bacteria recovered from
the peritoneal ﬂuid, grouped according to the pre-
operative length of stay and previous use of any
antimicrobial therapy, are summarised in Table 4.
Susceptibility rates ranged from 14% to 100%,
Table 3. Risk of acquiring multidrug-resistant bacteria according to the pre-operative length of hospital stay (< or ‡ 5
days) and use of previous antimicrobial therapy
Pre-operative length of hospital stay
<5 days; previous antimicrobial therapy
(–) and (+) (no. of patients = 47)
Pre-operative length of hospital stay ‡5 days
Previous antimicrobial
therapy (–)
(no. of patients = 22)
Previous antimicrobial
therapy (+)
(no. of patients = 24)
Multidrug resistance (+) 1 (2%) 4 (18%) 9 (38%)
Multidrug resistance (–) 46 (98%) 18 (82%) 15 (62%)
OR (95% CI) 1 10.2 (1.1–97.8); p 0.044 27.6 (3.2–236.1); p 0.003
Type and number of
multidrug-resistant
bacteria recovered
Enterococcus spp. (n = 1) Enterobacter spp. (n = 3)
Escherichia coli (n = 1)
MRSA (n = 3)
Enterobacter spp. (n = 5)
Pseudomonas aeruginosa (n = 2)
MRSA, methicillin-resistant Staphylococcus aureus.
Table 4. Antibiotic susceptibility rates (%) for aerobic Gram-negative bacteria and aerobic Gram-positive cocci isolated,
grouped according to pre-operative length of hospital stay (<5 or ‡5 days) and the use of previous antimicrobial therapy
Pre-operative length of hospital stay <5 days;
previous antimicrobial therapy (–) and (+)
Pre-operative length of hospital stay ‡5 days
Previous antimicrobial
therapy (–)
Previous antimicrobial
therapy (+)
Aerobic Gram-negative bacteria n = 52 n = 24 n = 21
Amoxycillin–clavulanic acid 62 54 14
Ticarcillin–clavulanic acid 90 67 50
Piperacillin–tazobactam 98 83 55
Cefotaxime 92 75 55
Ceftazidime 98 83 64
Cefepime 100 96 73
Imipenem 100 100 86
Gentamicin 100 83 82
Amikacin 100 92 100
Ciproﬂoxacin 96 92 59
Aerobic Gram-positive cocci n = 27 n = 21 n = 22
Amoxycillina 75 91 69
Oxacillinb 100 89 50
Gentamicinc 100 86 95
Vancomycinc 96 100 100
aSusceptibility for Enterococcus spp.
bSusceptibility for Streptococcus spp. and Staphylococcus spp.
cSusceptibility for Streptococcus spp., Enterococcus spp., and Staphylococcus spp.
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and from 50% to 100%, for Gram-negative and
Gram-positive bacteria, respectively. The efﬁcacy
of each antimicrobial regimen differed among
groups, particularly for Gram-negative bacteria.
DISCUSSION
The incidence of MDR bacteria in secondary
peritonitis in this prospective study was 15%.
Patients who had a pre-operative length of hos-
pital stay ‡5 days were at risk for developing an
MDR bacterial infection, especially when antibi-
otics had been used previously. Few studies have
evaluated the incidence of MDR bacteria in
secondary peritonitis. In a retrospective study of
100 cases of post-operative peritonitis, Mon-
travers et al. [2] found resistance (to at least one
antibiotic class to which the bacteria were usually
sensitive) in 70% of cases, and multidrug resist-
ance (resistance to at least two antibiotic classes to
which the bacteria were usually sensitive) in 37%
of cases. The differences in the deﬁnition of
multidrug resistance and the inclusion of both
community-acquired and nosocomial peritonitis
in the present study probably explain the dis-
crepancy in the results. If the present study had
been restricted to post-operative peritonitis, MDR
bacteria would have been observed in 31%
(11 ⁄ 35) of cases, similar to the ﬁgure reported by
Montravers et al. [2].
The therapeutic approach for secondary peri-
tonitis is differentiated typically into three main
categories: community-acquired peritonitis, no-
socomial post-operative peritonitis, and nosoco-
mial non-post-operative peritonitis (occurring
without surgical intervention). Antimicrobial
therapy for community-acquired peritonitis is
relatively well-codiﬁed [7,17–20]. Indeed, in this
context, the antimicrobial therapy must be tar-
geted at Enterobacteriaceae, particularly Esch. coli,
and anaerobes, especially Bacteroides fragilis, while
the need for speciﬁc therapy against Enterococcus
spp. remains controversial [7,18–20]. The man-
agement of post-operative peritonitis is different,
in that the bacteria are frequently resistant to
antimicrobial therapy, and it has been shown that
inadequate antimicrobial therapy prolongs hospi-
talisation and is associated with clinical failure
and a higher mortality rate [2,21]. In this context,
empirical antimicrobial therapy is based on the
local ecology, and frequently requires the use of
expanded-spectrum multidrug regimens that in-
clude an aminoglycoside or a quinolone, or a
carbapenem and vancomycin [7,22]. Nosocomial
non-post-operative peritonitis represents a partic-
ular entity that, until recently, was classiﬁed as
post-operative peritonitis with a high frequency
of resistant bacteria [7,22]. However, a large
multicentre study in France has shown that the
microbiological characteristics of nosocomial non-
post-operative peritonitis mimic those of commu-
nity-acquired peritonitis. The empirical antimi-
crobial therapy usually administered for
community-acquired peritonitis remains appro-
priate, although nosocomial bacteria have also
been recovered, without being described precisely
[6]. In contrast, the North American Guidelines
recommend the use of expanded-spectrum anti-
biotics for pre-operative patients with prolonged
stays, and prolonged (>2 days) pre-operative
antimicrobial therapy because of the high risk
for acquisition of nosocomial ﬂora [7]. Interest-
ingly, no precise duration of hospitalisation was
mentioned in these guidelines, whereas the pre-
sent study found that a cut-off threshold of 5 days
had the best sensitivity and speciﬁcity for pre-
dicting the acquisition of MDR bacteria.
According to the results obtained in the present
study, it is possible to propose a different thera-
peutic approach, based on an analysis of the risk-
factors for acquiring MDR bacteria. Three differ-
ent groups were identiﬁed: (i) patients with a pre-
operative length of hospital stay of <5 days, with
or without previous antimicrobial therapy, who
developed an intra-abdominal infection with
sensitive bacteria; (ii) patients with a pre-opera-
tive length of hospital stay of ‡5 days with
previous antimicrobial therapy; and (iii) patients
without previous antimicrobial therapy. Follow-
ing previous use of antimicrobial therapy, the risk
of acquiring an MDR Gram-negative organism
(Enterobacter spp. producing a cephalosporinase
or P. aeruginosa resistant to ticarcillin and ceftazi-
dime) and ⁄ or MRSA, was high (9 ⁄ 24 patients;
Table 3). In this context, empirical antimicrobial
therapy could be a combination of cefepime–
amikacin–metronidazole and vancomycin, or a
combination of imipenem–amikacin and vanco-
mycin. For patients with no previous antimicro-
bial therapy, a failure to isolate P. aeruginosa and
MRSA allows the use of simpler combinations of
cefepime–amikacin–metronidazole, or imipenem–
amikacin (Table 3). However, despite a prolonged
pre-operative length of stay, with or without
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previous antibiotic use, a large proportion of the
patients were infected with sensitive microorgan-
isms, which emphasises that antimicrobial ther-
apy must be reconsidered as soon as antimicrobial
susceptibility results are available.
In conclusion, the main interest of this stratiﬁed
approach is that it enables the use of targeted
empirical antimicrobial therapy based on two
simple criteria, and that it limits the use of
expanded-spectrum antimicrobial agents in pa-
tients with post-operative peritonitis. However,
this work has several limitations. First, as it is a
single-centre study, the results cannot be extra-
polated to another hospital; indeed, knowledge of
the local bacterial ecology is an important param-
eter in the initiation of empirical antimicrobial
therapy, and intra-abdominal infection is no
exception to this rule [7]. In addition, only the
ﬁrst episode of intra-abdominal infection was
taken into account, whereas multiple infections
represent a more complex situation in which
antibiotics are not always necessary. Neverthe-
less, knowledge of two simple parameters (pre-
operative length of hospital stay and previous use
of antimicrobial therapy) may provide a more
rational basis for selecting the initial therapy of
patients with secondary peritonitis.
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